Exai Bio’s RNA-Based Liquid Biopsy Platform May Detect Colorectal Cancer Early
Exai Bio presented data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs.”
Read MorePosted by Andy Lundin | Sep 20, 2022 | Colorectal |
Exai Bio presented data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs.”
Read MorePosted by Chris Wolski | Sep 16, 2022 | Gastrointestinal Infections |
Prometheus Laboratories Inc. is partnering with Takeda to nationally launch CDPATH, a prognostic tool for Crohn’s disease patients.
Read MorePosted by Chris Wolski | Sep 15, 2022 | Sexually Transmitted Diseases |
Psomagen Incorporated and Kean Health announced the launch of Kean V and Kean V+, a vaginal microbiome test.
Read MorePosted by Chris Wolski | Sep 14, 2022 | Cancer |
Patients at St. Elizabeth Healthcare can be screened for 50 different types of cancer, thanks to a new cancer-detecting blood test.
Read MorePosted by Tonya Manning | Sep 8, 2022 | Podcasts |
In the wake of the U.S. Supreme Court’s overturning of Roe v. Wade, there’s been a lot of focus on how it’s affecting the delivery of health care, but one area that hasn’t been as focused on is what this decision means for pre-natal testing and how labs and providers of tests need to be navigating this new landscape.
Read More